LPTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LPTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Leap Therapeutics's Future 3-5Y Total Revenue Growth Rate is N/A.
For the Biotechnology subindustry, Leap Therapeutics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Leap Therapeutics's Future 3-5Y Total Revenue Growth Rate falls into.
Leap Therapeutics (NAS:LPTX) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Leap Therapeutics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Jason Baum | officer: Chief Scientific Officer | LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
Patricia A. Martin | director | 316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260 |
Christian M Richard | director | 100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110 |
Richard Schilsky | director | LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
Beigene, Ltd. | 10 percent owner | C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Christine Granfield | officer: VP, Head of Reg Affairs/Qual | C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
John Mark O'mahony | officer: Chief Manufacturing Officer | C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
Cynthia Sirard | officer: Chief Medical Officer | C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Christopher Mirabelli | director, 10 percent owner, officer: CEO,Pres,Chairman of the Board | 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
Augustine Lawlor | 10 percent owner, officer: Chief Operating Officer | 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
Douglas E Onsi | 10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. | C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Healthcare Ventures Ix, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By PRNewswire • 01-16-2024
By GuruFocus Research • 02-07-2024
By PRNewswire • 01-03-2024
By PRNewswire • 11-26-2024
By GuruFocus Research • 02-07-2024
By PRNewswire • 04-11-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.